Stay updated on Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Sign up to get notified when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.

Latest updates to the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page shows a new revision tag (v3.6.3), signaling a backend update; this change does not appear to affect the study details displayed.SummaryDifference0.1%

- Check19 days agoChange DetectedThe page now displays a newer site revision label (v3.6.2) replacing the previous v3.6.0, indicating a software release for the page. This update does not alter the study details, eligibility criteria, or results displayed on the page.SummaryDifference0.1%

- Check33 days agoChange DetectedThe study page now shows that no participants are being sought, updating the recruitment status to completed. Additionally, new help and navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), and a small formatting change updated the Intervention/Treatment label while the site revision progressed from v3.5.5 to v3.6.0.SummaryDifference0.4%

- Check40 days agoChange DetectedThe page now displays Revision: v3.5.5, replacing the previous Revision: v3.5.4, indicating an update to the page's versioning.SummaryDifference0.1%

- Check61 days agoChange DetectedA newer revision tag was added (v3.5.4) and the previous revision tag (v3.5.3) was removed, signaling an updated version of the study record.SummaryDifference0.1%

- Check82 days agoChange DetectedThe page footer’s site revision indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a platform/release change rather than any change to the trial information.SummaryDifference0.1%

Stay in the know with updates to Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.